James West, Ph.D., and colleagues treated BMPR2 mutant mice with the estrogen
inhibitors anastrozole, fulvestrant and tamoxifen.
FDA approves the aromatase
inhibitors anastrozole and exemestane for the adjuvant treatment of hormone receptor - positive early - stage breast cancer.
Not exact matches
Aromatase
inhibitors, such as
anastrozole, exemestane, and letrozole.
An anti-aromatase
inhibitor such as
anastrozole will help limit any estrogenic action that could occur from the steroid Nilevar.